Oral Antivirals for COVID-19: Practical Considerations for Patient Selection, Evaluation for Safe Use, Monitoring and Referral
Nirmatrelvir/ritonavir continues to be the drug of choice for patients who present with mild-moderate COVID-19 that are at high risk for progression to severe disease. Drug-drug interactions with nirmatrelvir/ritonavir are complex which is why pharmacists are the perfect providers to manage them safely. Many of the drug-drug interactions that occur can be mitigated with a medication hold, dose reduction or additional monitoring. This interactive module will review the current NIH COVID-19 treatment guidelines, mechanism and process for drug-interaction analysis and intervention, and suggestions for physician referral. You’ll walk through several interactive cases and make decisions for patients based on their comorbidities, medication regimen and drug-drug interactions that exist.